An optimized cognitive biomarker that accurately predicts future cognitive decline and improves the detection of MCI and early dementia

Abstract

Background: Mild Cognitive Impairment (MCI) affects over 12 million individuals in the US, 50% of whom will progress to Alzheimer's disease or another form of dementia in 3‐5 years. But 90% of individuals with MCI remain undiagnosed due to challenges in screening.

The paper